Cas no 3778-73-2 (Ifosfamide)

Ifosfamide is an alkylating chemotherapeutic agent belonging to the nitrogen mustard class. It is primarily used in the treatment of various cancers, including sarcomas, lymphomas, and testicular cancer. The compound functions by cross-linking DNA strands, inhibiting tumor cell proliferation. A key advantage of ifosfamide is its broad-spectrum activity against both solid and hematologic malignancies. It is often administered in combination regimens due to its synergistic effects with other antineoplastic agents. The prodrug nature of ifosfamide allows for targeted activation in tumor tissues, enhancing therapeutic efficacy while minimizing systemic toxicity. Proper hydration and concomitant use of uroprotective agents, such as mesna, are recommended to mitigate hemorrhagic cystitis, a common side effect.

Ifosfamide structure

Product Name:Ifosfamide

CAS No:3778-73-2

MF:C₇H₁₅Cl₂N₂O₂P

MW:261.085960626602

MDL:MFCD00057374

CID:44484

PubChem ID:329815295

Update Time:2026-01-04

Ifosfamide Chemical and Physical Properties

Names and Identifiers

- Ifosfamide
- 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
- 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-
- 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
- 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
- 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
- A 4942
- Asta Z 4942
- Cyfos
- Holoxan
- Holoxan 1000
- Ifex
- Ifosfamid
- Iphosphamid
- Iphosphamid(e)
- Isoendoxan
- Isofosfamide
- Isophosphamide
- Mitoxana
- MJF 9325
- N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
- N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
- Naxamide
- Z4942
- N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
- 3-(2-chloroethyl)-2-[(2-chloroethyl)-amino]-2-oxo-1,3,2-oxazaphosphorinane
- 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydrochloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
- Ifex N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide
- ifosphamide
- ilfosfamide
- iphosphamide
- rac-iphosphamide
- N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide
- I-Phosphamide
- Ifsofamide
- Ifosfamidum
- Ifosfamida
- isosfamide
- Ifosfamidum [INN-Latin]
- Ifosfamida [INN-Spanish]
- ifomide
- Z 4942
- NSC109724
- 3-(2-Chloroethyl)-2-((2-chloroethyl)
- SCHEMBL4885
- IFOSFAMIDE [INN]
- 3778-73-2
- NCI-CO1638
- CCG-213464
- IFOSFAMIDE [VANDF]
- CS-1424
- CHEMBL1024
- WLN: T6NPOTJ AM2G BO B2G
- AB00513932-06
- Ifosfamidum (INN-Latin)
- IFO-Cell
- N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
- starbld0001221
- SW197177-4
- 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,2-oxazaphosphorine oxide
- CCRIS 352
- NCGC00179435-02
- SR-05000002022-5
- ISOPHOSPHAMIDE (IARC)
- N,N-BIS(BETA-CHLOROETHYL)-AMINO-N'-O-PROPYLENE-PHOSPHORIC ACID ESTER DIAMIDE
- 3-(2-Chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,2-oxaazaphosphorin 2-oxide
- 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
- HMS3654B15
- IFOSFAMIDE [USAN]
- MLS002154021
- AB02316
- MJF-9325
- Iso Endoxan
- IFOSFAMIDE [MART.]
- (S)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide
- HMS3714H07
- AB00513932_09
- 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
- IFOSFAMIDE (MART.)
- HMS3374B08
- HSDB 7023
- Asta Z-4942
- 1,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
- EN300-7476797
- Z-4942
- Seromida
- Isophosphamide,(S)
- N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
- ISOPHOSPHAMIDE [IARC]
- IFOSFAMIDE (USP-RS)
- Prestwick3_000833
- HMS2090M12
- NSC-109724
- 2-oxo-N,3-bis-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine
- 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
- IFOSFAMIDE [USP-RS]
- Ifosfamide, European Pharmacopoeia (EP) Reference Standard
- Tox21_201815
- NCGC00179435-06
- Tox21_302775
- N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
- NSC-759154
- 2,3-(N,N(,)-BIS(2-CHLOROETHYL)DIAMIDO)-1,3,2-OXAZAPHOSPHORIDINOXY
- Tox21_110539
- N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphinan-2-amine 2-oxide #
- HMS2232O10
- IFOSFAMIDE (USP MONOGRAPH)
- NS00000356
- HMS2093N07
- Pharmakon1600-01505480
- IFOSFAMIDE (EP MONOGRAPH)
- N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l;{5}-oxazaphosphinan-2-amine
- NCI-C01638
- BCP06596
- MFCD00057374
- Ifosfamide (JAN/USP/INN)
- IFOSFAMIDE [HSDB]
- NCGC00179435-01
- BI166243
- NSC759154
- NCI60_000233
- 66849-34-1
- AC-2113
- IFOSFAMIDE [EP IMPURITY]
- DB01181
- 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,2-oxazaphosphorine 2-oxide
- 3-(2-CHLOROETHYL)-2-((2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE-2 -OXIDE
- AB00513932-07
- SY066721
- N-(2-CHLORAETHYL)-N'-(2 CHLOROETHYL)-N'-o-PROPYLEN-PHOSPHORSAEUREESTER-DIAMID
- 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
- {3-(2-Chloroethyl)-2-[(2-
- SBI-0206804.P001
- IFOSFAMIDE [EP MONOGRAPH]
- D00343
- 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,2-oxazaphosphorineoxide
- N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine
- N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
- Iso-Endoxan
- Ifomida
- N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
- Ifex (TN) (Bristol Meyers)
- Prestwick2_000833
- NCGC00259364-01
- (2-CHLORO-ETHYL)-[(R)-3-(2-CHLORO-ETHYL)-2-OXO-2LAMBDA5-[1,3,2]OXAZAPHOSPHINAN-2-YL]-AMINE
- SR-05000002022-3
- Ifosfamide [USAN:USP:INN:BAN:JAN]
- Ifosfamide (USAN:USP:INN:BAN:JAN)
- Ifosfamide in bulk
- UNII-UM20QQM95Y
- 2,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
- CAS-3778-73-2
- 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
- Ifosfamide - Bio-X
- Q-101874
- GTPL7201
- NCGC00016639-01
- IFOSFAMIDE [MI]
- NCGC00179435-07
- DTXSID7020760
- Ifosfamida (INN-Spanish)
- Prestwick1_000833
- FT-0670282
- s1302
- EINECS 223-237-3
- IFOSFAMIDE [JAN]
- AS-10978
- (R)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide
- AB00513932_10
- BRN 0611835
- BPBio1_000865
- I0713
- Holoxane
- AKOS005711213
- FT-0603650
- N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
- BSPBio_000785
- NSC 109724
- IFOSFAMIDE [ORANGE BOOK]
- Tronoxal
- Ifosfamide, >=98%
- Q418560
- UM20QQM95Y
- A823873
- NCGC00179435-03
- AB00513932
- CHEBI:5864
- 2H-1,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
- IFOSFAMIDE [USP MONOGRAPH]
- Tox21_110539_1
- IFOSFAMIDE [WHO-DD]
- Ifosfamide, analytical reference material
- Prestwick0_000833
- ISOCYCLOPHOSPHAMIDE
- N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
- Ifosfamid A
- HMS2097H07
- SMR001233348
- SR-05000002022
- BDBM189358
- 2,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-
- HMS1570H07
- Ifosfamide Sterile
- IFOSFAMIDE (EP IMPURITY)
- Ifosfamide; (RS)-N,3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
- 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide
- IFEX (TN)
- BRD-A67097164-001-11-2
- HY-17419
- C07047
- 2H-1,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
- Ifosfamide, British Pharmacopoeia (BP) Reference Standard
- L01AA06
- 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one
- SR-05000002022-1
- 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one
- {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,} 2-oxazaphosphorine oxide
- Ifosfamide, United States Pharmacopeia (USP) Reference Standard
- 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorineoxide
- 3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide
- DTXCID90760
- Ifoxan
- Ifolem
- NCGC00256413-01
- SPBio_002706
- AB00513932-08
- DB-049196
- STL058690
- BRD-A67097164-001-18-7
- BRD-A67097164-001-17-9
- BBL028071
- MDL： MFCD00057374
- Inchi： 1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
- InChI Key： HOMGKSMUEGBAAB-UHFFFAOYSA-N
- SMILES： ClCCN1CCCOP1(NCCCl)=O

Computed Properties

Exact Mass: 260.02500
Monoisotopic Mass: 260.025
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 1
Hydrogen Bond Acceptor Count: 4
Heavy Atom Count: 14
Rotatable Bond Count: 5
Complexity: 218
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 1
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Surface Charge: 0
Tautomer Count: 2
XLogP3: 0.9
Topological Polar Surface Area: 41.6

Experimental Properties

Color/Form: Crystalline solid
Density: 1.33
Melting Point: 48 oC
Boiling Point: 336.1°C at 760 mmHg
Flash Point: 157.1 °C
PSA: 51.38000
LogP: 2.21280

Ifosfamide Security Information

Symbol:
Signal Word：Danger
Hazard Statement： H301,H319
Warning Statement： P301+P310,P305+P351+P338
Hazardous Material transportation number：UN 3249
WGK Germany：3
Hazard Category Code： 25-36
Safety Instruction： 26-45
RTECS：RP6050000
Hazardous Material Identification：
HazardClass：6.1
PackingGroup：III
Toxicity：LD50 in rats (mg/kg): 160 i.p. (Arnold, 1973); also reported as 150 i.p. (Brock)
Storage Condition：2-8°C
Safety Term：6.1(b)
Packing Group：III
Risk Phrases：R25
Packing Group：III
Hazard Level：6.1(b)

Ifosfamide Customs Data

HS CODE：2934999090
Customs Data：

China Customs Code:
2934999090

Overview:

2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

Declaration elements:

Product Name, component content, use to

Summary:

2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Ifosfamide Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.	I812171-25g	Isophosphamide	3778-73-2	98%	25g	￥2,994.00	2022-01-14
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.	I0060000	Ifosfamide	3778-73-2	European Pharmacopoeia (EP) Reference Standard		￥2654.27	2022-02-23
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.	1336205-500MG	Ifosfamide	3778-73-2		500mg	￥3302.56	2024-12-26
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.	I0713-1G	Ifosfamide	3778-73-2	>95.0%(GC)(T)	1g	￥490.00	2024-04-16
TRC	I265000-50mg	Ifosfamide	3778-73-2		50mg	$ 63.00	2023-09-07
TRC	I265000-100mg	Ifosfamide	3778-73-2		100mg	$ 68.00	2023-09-07
TRC	I265000-250mg	Ifosfamide	3778-73-2		250mg	$ 98.00	2023-09-07
TRC	I265000-1g	Ifosfamide	3778-73-2		1g	$170.00	2023-05-18
TRC	I265000-5g	Ifosfamide	3778-73-2		5g	$809.00	2023-05-18
TRC	I265000-10g	Ifosfamide	3778-73-2		10g	$1216.00	2023-05-18

Ifosfamide Suppliers

Zhengzhou Baoyu Pharmaceutical Co., Ltd.

Gold Member

Audited Supplier

(CAS:3778-73-2)Ifosfamide

Order Number:LE157

Stock Status:in Stock

Quantity:5KG/1KG/25KG/100KG

Purity:99% HPLC

Pricing Information Last Updated:Thursday, 14 August 2025 14:44

Price ($):negotiated

Email:[email protected]

Ifosfamide Spectrogram

1H NMR

JEOL

CDCl3

GC-MS

13C NMR

JEOL

CDCl3

Ifosfamide Related Literature

1. Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works

Kevin V. Thomas,Christian Dye,Martin Schlabach,Katherine H. Langford J. Environ. Monit. 2007 9 1410
2. Separation of ifosfamide and its degradation products using micellar electrokinetic chromatography

Shannon Hill,John Aexiou,Peter E. Kavanagh,Peter C. Livingstone,Ross A. Shalliker,James Soscic Anal. Commun. 1996 33 235
3. Multi-residue determination of micropollutants in Nigerian fish from Lagos lagoon using ultrasound assisted extraction, solid phase extraction and ultra-high-performance liquid chromatography tandem mass spectrometry

Idera Fabunmi,Natalie Sims,Kathryn Proctor,Aderonke Oyeyiola,Temilola Oluseyi,Kehinde Olayinka,Barbara Kasprzyk-Hordern Anal. Methods 2020 12 2114
4. Glucose conjugation for the specific targeting and treatment of cancer

Emilia C. Calvaresi,Paul J. Hergenrother Chem. Sci. 2013 4 2319
5. Theoretical use of boron nitride nanotubes as a perfect container for anticancer molecules

M. El Khalifi,E. Duverger,T. Gharbi,H. Boulahdour,F. Picaud Anal. Methods 2016 8 1367

Related Categories

Additional information on Ifosfamide

Introduction to Ifosfamide (CAS No. 3778-73-2): Mechanism, Applications, and Recent Research Developments

Ifosfamide, a chemotherapeutic agent with the chemical formula C₉H₁₃N₂O₂F, is widely recognized for its significant role in the treatment of various cancers. Its CAS number, 3778-73-2, uniquely identifies this compound in the chemical database, underscoring its importance in pharmaceutical research and development. This compound belongs to the class of alkylating agents and has been a cornerstone in oncology for decades.

The primary mechanism of action of Ifosfamide involves the formation of highly reactive alkylating species that bind to DNA, leading to cross-linking and ultimately inhibiting DNA replication and transcription. This mechanism is particularly effective against rapidly dividing cells, making it a potent treatment for a variety of malignancies. The compound's efficacy has been demonstrated in the management of bladder cancer, testicular cancer, and certain leukemias and lymphomas.

In recent years, significant advancements have been made in understanding the pharmacological properties of Ifosfamide. One notable area of research has focused on its metabolic byproducts, particularly ifosfamide-derived chloroethyl derivatives. These metabolites are known to contribute to the drug's cytotoxic effects but also pose challenges such as urotoxicity. Recent studies have explored strategies to mitigate these side effects while maintaining therapeutic efficacy.

Moreover, the development of novel formulations and delivery systems has enhanced the therapeutic potential of Ifosfamide. For instance, sustained-release formulations have been investigated to improve patient compliance and reduce systemic toxicity. Additionally, combination therapies involving Ifosfamide with other chemotherapeutic agents or targeted therapies have shown promising results in clinical trials, particularly in cases of refractory or metastatic cancers.

The role of Ifosfamide in immunotherapy has also gained traction in recent years. Preclinical studies suggest that Ifosfamide can modulate immune responses by enhancing T-cell activity and reducing immunosuppressive checkpoints. This finding opens up new avenues for treating cancer patients who may not respond well to traditional chemotherapy alone.

Another area of interest has been the genetic variability among patients that influences their response to Ifosfamide therapy. Genetic markers such as polymorphisms in genes involved in drug metabolism (e.g., CYP3A4 and UGT1A1) have been identified as potential predictors of treatment outcomes. Personalized medicine approaches based on these genetic profiles could lead to more effective and safer use of Ifosfamide in clinical practice.

Recent clinical trials have highlighted the importance of supportive care measures in patients receiving Ifosfamide therapy. These measures include prophylactic antiemetics to manage nausea and vomiting, hydration protocols to prevent ifosfamide-induced hemorrhagic cystitis, and monitoring for bone marrow suppression. Such comprehensive care strategies have improved patient quality of life and treatment outcomes.

The future directions for research on Ifosfamide are multifaceted. Efforts are underway to develop more selective alkylating agents that target cancer cells while sparing healthy tissues. Additionally, exploring the role of Ifosfamide in combination with immunotherapy and targeted therapies holds great promise for overcoming drug resistance and improving long-term survival rates.

In conclusion, Ifosfamide (CAS No. 3778-73-2) remains a vital component in the oncology arsenal due to its potent antitumor activity. Ongoing research continues to uncover new mechanisms of action, optimize treatment protocols, and enhance patient outcomes. As our understanding of cancer biology evolves, so too will our ability to harness the full potential of this remarkable compound.

3778-73-2 (Ifosfamide) Related Products

Recommended suppliers